Illuminate is a clinical study for Leber congenital amaurosis. This page provides patients, their families and care givers with information about the trial and trial participation.
Illuminate - Phase 2/3 clinical trial for CEP290 mediated Leber congenital amaurosis
What is Illuminate?
Illuminate is the name of a clinical trial which aims to study whether the investigational RNA therapy sepofarsen is effective and safe for people with Leber congenital amaurosis 10 (LCA10) due to the most common p.Cys998X mutation, also known as c.2991+1655A>G, in the CEP290 gene. This Phase 2/3 pivotal trial is the second clinical study to investigate sepofarsen. If you are interested in joining this trial, please read about the eligibility criteria.
What is sepofarsen?
Sepofarsen (formerly known as QR-110) is an investigational RNA therapy that aims to restore vision in people that have LCA due to the p.Cys998X mutation in the CEP290 gene.
How is the Illuminate trial set up?
Clinical trials are used by researchers to find out whether new medicines are effective and safe. Key aspects of the Illuminate trial are the following:
- Illuminate aims to find out whether sepofarsen is effective at improving vision, safe and well-tolerated;
- The study will enroll around 30 participants, including adults and children (age 8 and up);
- Study participants will be randomized into three equal groups. All participants will receive sepofarsen during the trial, but the dose level and start of dosing differ per group. They will be randomly assigned to one of the following study groups:
- Group 1: will receive intravitreal injections (injection into the eye) with dose 1 of sepofarsen.
- Group 2: will receive intravitreal injections with dose 2 of sepofarsen.
- Group 3: will receive the sham procedure for the first 12 months in which an intravitreal injection is mimicked but no injection and no study medicine are given. After 12 months this group will receive sepofarsen at one of the two dose levels in the subsequent 12 months.
Participants will receive the study medicine or the sham procedure up to a maximum of 5 times in the chosen (study) eye, which is the eye with the worse vision. The treatment or sham procedure will be given on day 1, in months 3, 9, 15 and 21 of the study.
Is Illuminate for me?
The information below outlines the main criteria for participation in the trial. Participants must:
- Have an established genetic diagnosis of LCA caused by the p.Cys998X mutation (also known as c.2991+1655A>G) in the CEP290 gene;
- Be 8 years of age or older;
- Be able to communicate verbally;
- Not have any planned surgery on the eye during (and just prior to the start of) the Illuminate trial;
- Not participate in another clinical study during the Illuminate trial.
Genetic testing is the only way to receive an accurate diagnosis and will help find out if there are treatments or clinical trials available.Genetic testing
How to participate in the clinical trial?
We recommend that you discuss your situation and suitability for the trial with your doctor. They will be able to refer you to a medical center where the Illuminate trial is conducted. You can also contact the trial center directly, their contact details are provided below.
Illuminate is currently open at the following locations. If there is no location near you this does not have to limit your ability to join the trial.
Select a country to find a list of Illuminate clinical trial locations:
University of Miami - Bascom Palmer Eye Institute
Miami, Florida, United States, 33156
Contact: Doris Caldwell | 305-482-5251
Principal Investigator: Byron Lam
University of Iowa
Iowa City, Iowa, United States, 52242
Contact: Jean Walshire | 319-467-5183
Contact: Mitch Martin | 319-467-5182
Principal Investigator: Stephen Russell
Columbia University Medical Center
New York, New York, United States, 10032
Contact: Maribel Rodriguez | 212-305-9535
Principal Investigator: Steven Brooks
Casey Eye Institute - Oregon Health & Science University
Portland, Oregon, United States, 97239-4197
Contact: Jennifer Blackerby | 503-494-0020
Principal Investigator: Paul Yang
University of Pennsylvania - Center for Advanced Retinal & Ocular Therapeutics
Philadelphia, Pennsylvania, United States, 19104
Contact: Denise Pearson | 215-662-6396
Principal Investigator: Tomas Aleman
Baylor College of Medicine
Houston, Texas, United States, 77030
Contact: Margaret Olfson | 713-798-4037
Principal Investigator: Tahira Scholle, MD
Universitair Ziekenhuis Gent (UZ)
Contact: Bart Leroy
Principal Investigator: Bart Leroy
INRET Clínica/ Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, MG, Brazil, 30150270
Principal Investigator: Fernanda Porto
Federal University of São Paulo - Hospital São Paulo (UNIFESP-HSP)
São Paulo, SP, Brazil, 04023-062
Contact: Juliana Sallum | +55 11 5576-4848 ext 2265
Principal Investigator: Juliana Sallum
The Hospital for Sick Children - SickKids
Toronto, Ontario, Canada, M5G 2L3
Contact: Vaishnavi Batmanabane | +1 416-813-7654 ext 301511
Principal Investigator: Elise Heon
McGill University Health Centre - Centre for Innovative Medicine
Montréal, Quebec, Canada, H4A 3J1
Contact: Christine Gannon | 1-514-934-1934 ext 23647
Contact: Ayan Ibrahim | 1-514-934-1934 ext 24925
Principal Investigator: Robert Koenekoop
Centre de maladies rares CHNO des Quinze Vingt
Hospital Civil de Strasbourg
Strasbourg, France, 67091
Contact: Hélène Dollfus | +33(0)3 88 11 67 53
Principal Investigator: Hélène Dollfus
Justus-Liebig Universität - Department of Ophthalmology
Gießen, Germany, 35392
Contact: Lyubomyr Lytvynchuk | +49-641-985-43803
Principal Investigator: Lyubomyr Lytvynchuk
University of Tuebingen - Inst. for Ophthalmic Research
Tuebingen, Germany, 72076
Contact: Andrea Rindtorff | +49 7071 29 87747
Principal Investigator: Katarina Stingl, MD
Eye Clinic University of Campania Luigi Vanvitelli
Naples, Italy, 80131
Contact: Carmela Acerra | +39 338 7630132
Principal Investigator: Francesca Simonelli
Amsterdam University Medica Center - Locatie AMC
Amsterdam, Netherlands, 1105 AZ
Contact: Monique Wezel | +31 205668618
Principal Investigator: Camiel Boon
Radboud Universitair Medisch Centrum
Nijmegen, Netherlands, 6525 GA
Contact: Chantal Buster-Franc | +31 243613212
Principal Investigator: Carel Hoyng
Het Oogziekenhuis Rotterdam
Rotterdam, Netherlands, 3011 BH
Contact: Marja Scheeres | +31 104023437
Principal Investigator: L. Ingeborgh van den Born
Moorfields Eye Hospital - NHS Foundation Trust
London, United Kingdom, EC1V 2PD
Contact: Shamima Akther | +44 0207 253 3411 ext 4246
Principal Investigator: Michel Michaelides
The above information is also available on worldwide clinical trial database clinicaltrials.gov with identifier (NCT number): NCT03913143.
What is CEP290 mediated Leber congenital amaurosis (LCA10)?
Leber congenital amaurosis (LCA) is an inherited retinal disease and the most common genetic cause of childhood blindness. For most of the approximately 15,000 people in the Western world that live with LCA, there is currently no approved treatment available. The disease usually appears in the first year of life and is characterized by progressive loss of vision. Other symptoms can include uncontrolled rapid eye movement, eye-poking, night blindness and sensitivity to light. Depending on the mutation, complete loss of vision can occur during early childhood.
LCA is a genetic disease that causes a mistake, or mutation, in the patient’s RNA. Because of the mutation, an essential protein in the eye cannot function, and this leads to the deterioration of the light detecting cells in the retina. The most common mutation causing LCA is the p.Cys998X mutation, also known as c.2991+1655A>G mutation in the CEP290 gene. This mutation causes Leber congenital amaurosis 10 (LCA10). Although there is little information on how many patients have LCA10, we believe approximately 2,000 people in the Western world have LCA10 due to this mutation.
Frequently asked questions
Below you will find answers to the most frequent questions about the Illuminate trial.
Intravitreal injection is one of the most commonly performed procedures for eye diseases. The inside of the eye is filled with a jelly-like fluid (vitreous). During an intravitreal injection, the eye doctor will inject medicine into the vitreous with a very small needle, after numbing the eye. The patient may feel some pressure but no pain. Learn more about intravitreal injection.
An RNA therapy is designed to correct the mistake, or mutation, in the RNA of someone with a genetic disease. By correcting the mistake, the RNA can then be used to create the protein that the cell needs, taking away the underlying cause of the disease. Learn more about how RNA therapy works.
Yes, travel and accommodation costs will be covered.
While available information on sepofarsen is encouraging, there is still much to learn about sepofarsen and its effects. Therefore, sepofarsen is currently not available outside clinical trials.
People participate in clinical trials for different reasons. Some participate because they want to learn more about their disease. Others participate because they want to help with the development of new treatments that could help them and others in the future.
If you take part in a clinical trial, you may be one of the first people to benefit from new study medication. Clinical trials follow a specific set of standards and are strictly regulated to help keep all participants safe. All clinical trials are reviewed and approved by a committee of independent experts (Ethics Committee or Institutional Review Board).
During a clinical trial, participants are carefully monitored. In addition to eye tests, general safety tests may be performed during study visits, such as blood tests, blood pressure, heart rate and temperature.
Ask a question
Didn't find the answer to your question yet? We'll gladly help you, please reach out using the form below, or email directly to firstname.lastname@example.org.
You might like this related content.